Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivorsopen access
- Authors
- Shim, S.; Kang, D.; Kim, N.; Han, G.; Lim, J.; Kim, H.; Park, J.; Lee, M.; Lee, J.E.; Kim, S.W.; Yu, J.; Chae, B.J.; Ryu, J.M.; Nam, S.J.; Lee, S.K.; Cho, J.
- Issue Date
- Jul-2022
- Publisher
- Korean Cancer Association
- Keywords
- Breast neoplasms; Cancer survivors; Financial stress; Quality of life; Validation study
- Citation
- Cancer Research and Treatment, v.54, no.3, pp 834 - 841
- Pages
- 8
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Cancer Research and Treatment
- Volume
- 54
- Number
- 3
- Start Page
- 834
- End Page
- 841
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/100024
- DOI
- 10.4143/CRT.2021.784
- ISSN
- 1598-2998
2005-9256
- Abstract
- Purpose: Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors. Materials and Methods: We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques. Results: The COST-K demonstrated good internal consistency, with a Cronbach's α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=-0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, -0.18; constipation, -0.14; diarrhea, -0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity. Conclusion: The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions. © 2022 by the Korean Cancer Association.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/100024)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.